Morgan Stanley
SVA

Morgan Stanley’s Sinovac Biotech, Ltd SVA Stock Holding History

Morgan Stanley’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$59.2K Hold
9,144
– – ﹤0.01% 6359
2025
Q4 		$59.2K Hold
9,144
– – ﹤0.01% 6384
2025
Q3 		$59.2K Buy
9,144
+800
+10% +$5.18K ﹤0.01% 6343
2025
Q2 		$54K Buy
+8,344
New +$54K ﹤0.01% 6337
2024
Q3 		– Sell
-7,824
Closed -$50.6K – 8177
2024
Q2 		$50.6K Buy
7,824
+900
+13% +$5.82K ﹤0.01% 6162
2024
Q1 		$44.8K Buy
+6,924
New +$44.8K ﹤0.01% 6256
2023
Q4 		– Sell
-6,879
Closed -$44.5K – 8093
2023
Q3 		$44.5K Buy
6,879
+2,313
+51% +$15K ﹤0.01% 6214
2023
Q2 		$29.5K Buy
+4,566
New +$29.5K ﹤0.01% 6419
2022
Q4 		– Sell
-4,141
Closed -$27K – 8202
2022
Q3 		$27K Buy
4,141
+200
+5% +$1.3K ﹤0.01% 6669
2022
Q2 		$26K Buy
+3,941
New +$26K ﹤0.01% 6895
2022
Q1 		– Sell
-3,941
Closed -$26K – 8428
2021
Q4 		$26K Hold
3,941
– – ﹤0.01% 7122
2021
Q3 		$26K Buy
3,941
+100
+3% +$660 ﹤0.01% 7004
2021
Q2 		$25K Buy
3,841
+1,341
+54% +$8.73K ﹤0.01% 6936
2021
Q1 		$16K Buy
2,500
+1,000
+67% +$6.4K ﹤0.01% 6812
2020
Q4 		$10K Buy
1,500
+100
+7% +$667 ﹤0.01% 6646
2020
Q3 		$9K Hold
1,400
– – ﹤0.01% 6321
2020
Q2 		$9K Hold
1,400
– – ﹤0.01% 6202
2020
Q1 		$9K Hold
1,400
– – ﹤0.01% 6064
2019
Q4 		$9K Hold
1,400
– – ﹤0.01% 6303
2019
Q3 		$9K Hold
1,400
– – ﹤0.01% 6257
2019
Q2 		$9K Hold
1,400
– – ﹤0.01% 6179
2019
Q1 		$9K Sell
1,400
-7,152
-84% -$47K ﹤0.01% 6229
2018
Q4 		$60K Sell
8,552
-206
-2% -$1.5K ﹤0.01% 5706
2018
Q3 		$66K Buy
8,758
+1,074
+14% +$7.75K ﹤0.01% 5808
2018
Q2 		$57K Buy
7,684
+5,404
+237% +$42.5K ﹤0.01% 5888
2018
Q1 		$20K Sell
2,280
-21,571
-90% -$178K ﹤0.01% 6138
2017
Q4 		$188K Sell
23,851
-625,997
-96% -$4.68M ﹤0.01% 5434
2017
Q3 		$4.58M Sell
649,848
-353,191
-35% -$2.41M ﹤0.01% 3047
2017
Q2 		$6.77M Sell
1,003,039
-1,718,873
-63% -$9.42M ﹤0.01% 2552
2017
Q1 		$15.6M Buy
2,721,912
+2,718,762
+86,310% +$15.7M ﹤0.01% 1780
2016
Q4 		$19K Sell
3,150
-46,143
-94% -$278K ﹤0.01% 6026
2016
Q3 		$291K Sell
49,293
-979
-2% -$5.76K ﹤0.01% 4821
2016
Q2 		$298K Sell
50,272
-2,500
-5% -$15.3K ﹤0.01% 4736
2016
Q1 		$337K Sell
52,772
-20,090
-28% -$121K ﹤0.01% 4659
2015
Q4 		$417K Sell
72,862
-140,154
-66% -$754K ﹤0.01% 4668
2015
Q3 		$1.08M Buy
213,016
+146,095
+218% +$774K ﹤0.01% 4039
2015
Q2 		$352K Sell
66,921
-31,652
-32% -$167K ﹤0.01% 4935
2015
Q1 		$488K Sell
98,573
-18,106
-16% -$89.2K ﹤0.01% 4669
2014
Q4 		$610K Sell
116,679
-60,622
-34% -$309K ﹤0.01% 4526
2014
Q3 		$853K Buy
177,301
+94,739
+115% +$509K ﹤0.01% 4178
2014
Q2 		$466K Buy
82,562
+53,288
+182% +$324K ﹤0.01% 4631
2014
Q1 		$210K Sell
29,274
-35,333
-55% -$234K ﹤0.01% 5096
2013
Q4 		$396K Sell
64,607
-92,812
-59% -$559K ﹤0.01% 4619
2013
Q3 		$942K Buy
157,419
+35,293
+29% +$169K ﹤0.01% 3835
2013
Q2 		$480K Buy
+122,126
New +$454K ﹤0.01% 4290

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Morgan Stanley's SVA Position: Q1 2026 in Review

Morgan Stanley held its Sinovac Biotech, Ltd (SVA) position steady in Q1 2026 at 9,144 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6359.

Morgan Stanley first reported a position in SVA in Q2 2013 and has held it in 45 quarters since. The position peaked at $15.6M in Q1 2017. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Morgan Stanley held 9,144 shares of Sinovac Biotech, Ltd worth $59.2K as of Q1 2026.
  • Morgan Stanley left its Sinovac Biotech, Ltd share count unchanged in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6359 holding.
  • Morgan Stanley first reported a position in Sinovac Biotech, Ltd in Q2 2013 and has held it in 45 quarters since.
  • Morgan Stanley's Sinovac Biotech, Ltd position peaked at $15.6M in Q1 2017.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.